INVESTIGADORES
CROCI RUSSO Diego Omar
artículos
Título:
A UNIQUE GALECTIN SIGNATURE IN HUMAN PROSTATE CANCER PROGRESSION SUGGESTS GALECTIN-1 AS A KEY TARGET FOR TREATMENT OF ADVANCED DISEASE
Autor/es:
DIEGO J. LADERACH; GENTILINI LD; GIRIBALDI L; CÁRDENAS DELGADO VM; LG NUGNES; CROCI DO; NAKOUZI N; SACCA P; CASAS G; MAZZA O; SHIPP MA; VAZQUEZ E; CHAUCHEREAU A; KUTOK JL; ELOLA MT; DANIEL COMPAGNO; G. A. RABINOVICH
Revista:
CANCER RESEARCH
Editorial:
AMER ASSOC CANCER RESEARCH
Referencias:
Lugar: Philadelphia; Año: 2013 p. 86 - 96
ISSN:
0008-5472
Resumen:
Galectins, a family of glycan-binding proteins, influence tumor progression by modulating interactions
between tumor, endothelial, stromal, and immune cells. Despite considerable progress in identifying the roles
of individual galectins in tumor biology, an integrated portrait of the galectin network in different tumor
microenvironments is still missing. We undertook this study to analyze the "galectin signature" of the human
prostate cancer microenvironment with the overarching goal of selecting novel-molecular targets for prognostic
and therapeutic purposes. In examining androgen-responsive and castration-resistant prostate cancer cells and
primary tumors representing different stages of the disease, we found that galectin-1 (Gal-1) was the most
abundantly expressed galectin in prostate cancer tissue and was markedly upregulated during disease progres-
sion. In contrast, all other galectins were expressed at lower levels: Gal-3, -4, -9, and -12 were downregulated during
disease evolution, whereas expression of Gal-8 was unchanged. Given the prominent regulation of Gal-1 during
prostate cancer progression and its predominant localization at the tumor-vascular interface, we analyzed the
potential role of this endogenous lectin in prostate cancer angiogenesis. In human prostate cancer tissue arrays,
Gal-1 expression correlated with the presence of blood vessels, particularly in advanced stages of the disease.
Silencing Gal-1 in prostate cancer cells reduced tumor vascularization without altering expression of other
angiogenesis-related genes. Collectively, our findings identify a dynamically regulated "galectin-specific signa-
ture" that accompanies disease evolution in prostate cancer, and they highlight a major role for Gal-1 as a tractable
target for antiangiogenic therapy in advanced stages of the disease. Cancer Res; 73(1); 86?96. !2012 AACR